These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
456 related articles for article (PubMed ID: 31264067)
1. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis. Ishikawa M; Iwasa S; Nagashima K; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Saruta M; Boku N Invest New Drugs; 2020 Apr; 38(2):533-540. PubMed ID: 31264067 [TBL] [Abstract][Full Text] [Related]
2. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group. Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230 [TBL] [Abstract][Full Text] [Related]
3. Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer. Okunaka M; Kotani D; Demachi K; Kawazoe A; Yoshino T; Kawasaki T; Shitara K BMC Cancer; 2020 Nov; 20(1):1111. PubMed ID: 33198652 [TBL] [Abstract][Full Text] [Related]
4. Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial. Takashima A; Shitara K; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Kimura Y; Amagai K; Fujii H; Muro K; Esaki T; Choda Y; Takano T; Chin K; Sato A; Goto M; Fukushima N; Hara T; Machida N; Ohta M; Boku N; Shimura M; Morita S; Koizumi W Gastric Cancer; 2019 Jan; 22(1):155-163. PubMed ID: 29855738 [TBL] [Abstract][Full Text] [Related]
5. Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study). Nakasya A; Hagiwara Y; Ikoma T; Kurioka Y; Matsumoto T; Yamamoto Y; Tsuduki T; Kajiwara T; Moriwaki T; Nishina T; Yamashita N; Hyodo I Int J Clin Oncol; 2022 Apr; 27(4):684-694. PubMed ID: 35089459 [TBL] [Abstract][Full Text] [Related]
6. Impact of Second-line Chemotherapy on Prognosis: Response of Advanced Gastric Cancer to Taxanes Plus Ramucirumab. Masuda Y; Kananazawa Y; Matsuno K; Kakinuma D; Sakurazawa N; Ando F; Hagiwara N; Nomura T; Kato S; Yoshiyuki T; Yoshida H Anticancer Res; 2022 Mar; 42(3):1599-1605. PubMed ID: 35220257 [TBL] [Abstract][Full Text] [Related]
7. Dexamethasone is non-inferior to antihistamine plus dexamethasone premedication in preventing ramucirumab plus nab-paclitaxel infusion-related reactions in gastric cancer: a multicenter retrospective study. Negoro Y; Maeda T; Igarashi H; Shigemori M; Tanaka T; Ito Y; Tanizawa N; Nishikawa S; Ogawa J; Kamitani Y; Watanabe K; Tsukamoto H; Goto N Support Care Cancer; 2024 Oct; 32(10):704. PubMed ID: 39370483 [TBL] [Abstract][Full Text] [Related]
8. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer. Kinoshita J; Fushida S; Tsukada T; Oyama K; Watanabe T; Shoji M; Okamoto K; Nakanuma S; Sakai S; Makino I; Furukawa H; Hayashi H; Nakamura K; Inokuchi M; Nakagawara H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Fujimura T; Masakazu Y; Hirakawa K; Ohta T Oncol Rep; 2014 Jul; 32(1):89-96. PubMed ID: 24859429 [TBL] [Abstract][Full Text] [Related]
9. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer. Bando H; Shimodaira H; Fujitani K; Takashima A; Yamaguchi K; Nakayama N; Takahashi T; Oki E; Azuma M; Nishina T; Hironaka S; Komatsu Y; Shitara K Eur J Cancer; 2018 Mar; 91():86-91. PubMed ID: 29353164 [TBL] [Abstract][Full Text] [Related]
10. [Clinical Efficacy and Safety of Nab-Paclitaxel plus Ramucirumab Therapy in Patients with Unresectable Advanced or Recurrent Gastric Cancer]. Murakami K; Takeno A; Masuzawa T; Imada A; Takase K; Toya K; Yukawa Y; Kawai K; Sakamoto T; Katsura Y; Ohmura Y; Kagawa Y; Hata T; Takeda Y; Murata K Gan To Kagaku Ryoho; 2020 Mar; 47(3):493-495. PubMed ID: 32381926 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Ramucirumab/nab-paclitaxel for Previously Treated Advanced Gastric Cancer in Community Hospitals. Hashida S; Tanaka N; Takahashi Y; Onoda Y; Colvin HS; Ohashi R; Okamoto K Acta Med Okayama; 2021 Apr; 75(2):133-138. PubMed ID: 33953419 [TBL] [Abstract][Full Text] [Related]
12. A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis. Takahara N; Nakai Y; Ishigami H; Saito K; Sato T; Hakuta R; Ishigaki K; Saito T; Hamada T; Mizuno S; Kogure H; Yamashita H; Isayama H; Seto Y; Koike K Invest New Drugs; 2021 Feb; 39(1):175-181. PubMed ID: 32772340 [TBL] [Abstract][Full Text] [Related]
13. Ramucirumab Beyond Disease Progression After Paclitaxel Plus Ramucirumab in Gastric Cancer: A Phase II Trial. Sato Y; Yamashita H; Yagi K; Nomura S; Seto Y Anticancer Res; 2024 Jul; 44(7):3125-3131. PubMed ID: 38925825 [TBL] [Abstract][Full Text] [Related]
14. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157 [TBL] [Abstract][Full Text] [Related]
15. Real-World Effectiveness and Safety of Ramucirumab as a Second-Line Treatment for Patients with Unresectable Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in Japan and South Korea: A Systematic Literature Review. Zhang X; Zhou L; Zhou C; Shen L Adv Ther; 2024 Jun; 41(6):2112-2132. PubMed ID: 38619719 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial. Xu RH; Zhang Y; Pan H; Feng J; Zhang T; Liu T; Qin Y; Qin S; Yin X; Liu B; Ba Y; Yang N; Voon PJ; Tanasanvimon S; Zhou C; Zhang WL; Shen L Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1015-1024. PubMed ID: 34626550 [TBL] [Abstract][Full Text] [Related]
17. A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302). Tamura S; Taniguchi H; Nishikawa K; Imamura H; Fujita J; Takeno A; Matsuyama J; Kimura Y; Kawada J; Hirao M; Hirota M; Fujitani K; Kurokawa Y; Sakai D; Kawakami H; Shimokawa T; Satoh T Int J Clin Oncol; 2020 Dec; 25(12):2035-2043. PubMed ID: 32926227 [TBL] [Abstract][Full Text] [Related]
18. Clinical usefulness of ramucirumab plus paclitaxel for unresectable and recurrent gastric cancer. Hayase S; Yamada L; Ujiie D; Nirei A; Tada T; Hanayama H; Monma T; Saze Z; Ohki S; Kono K Fukushima J Med Sci; 2019; 65(1):6-12. PubMed ID: 30996218 [TBL] [Abstract][Full Text] [Related]
19. A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09). Kawabata R; Izawa N; Suzuki T; Nagahisa Y; Nishikawa K; Takahashi M; Nakamura M; Ishiguro A; Katsuya H; Hihara J; Manaka D; Negoro Y; Tsuji A; Takahashi T; Kochi M; Azuma M; Kadowaki S; Michimae H; Sunakawa Y; Ichikawa W; Fujii M Target Oncol; 2023 May; 18(3):359-368. PubMed ID: 37060430 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of ramucirumab plus paclitaxel therapy for advanced gastric cancer patients treated previously with docetaxel-containing chemotherapy. Kakuta T; Yabusaki H; Bamba T; Aizawa M; Nogami H; Nomura T; Matsuki A; Maruyama S; Takii Y; Nakagawa S Int J Clin Oncol; 2021 Apr; 26(4):684-693. PubMed ID: 33389346 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]